Product News – Spring Edition Product News – Spring Edition
IPT highlights some of the most recent exciting advancements in pharmaceutical manufacturing

Axplora announced a major milestone in its $60m investment programme in highly potent active pharmaceutical ingredient (HPAPI) manufacturing at its Farmabios site in Gropello Cairoli, Italy. The latest phase includes construction of a new 4,500m², three-storey R&D and lab hub, designed to accelerate development, expand execution capacity and deliver cost-efficient high-potency manufacturing at scale. The new facility will house state-of-the-art R&D labs, quality control laboratories, microbiology laboratories and integrated support areas, directly connected to existing manufacturing operations.

Co-locating development, analytics and large-scale HPAPI production within a single specialised site eliminates multi-site delays, improves scale-up efficiency and enhances overall programme economics. Once operational, the new facility will increase development and analytical throughput, reduce technology transfer complexity and compress timelines from early development to commercial production. Construction is underway, with completion targeted for February 2027.